U.S. markets close in 30 minutes

Palisade Bio, Inc. (PALI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7350+0.0250 (+0.92%)
As of 3:19PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.7100
Bid2.7300 x 1200
Ask2.7500 x 800
Day's Range2.7000 - 2.8500
52 Week Range2.2700 - 16.0200
Avg. Volume563,704
Market Cap35.363M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4540
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PALI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Palisade Bio, Inc.
    Daily – Vickers Top Insider Picks for 10/20/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    13 hours agoArgus Research
View more
  • GlobeNewswire

    Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

    CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces today that Chief Executive Officer Tom Hallam, Ph.D. will present at the H.C. Wainwright Global Investment Conference, which is being held virtually from September 13- 15, 2021. Dr. Hallam will deliver his corporate presentation, which will become available beginning on September 13 at 7:00 A

  • GlobeNewswire

    Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

    CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the second quarter ending June 30, 2021. Recent Corporate Highlights: Announced positive topline results from Phase 2 study of LB1148 by partner Newsoara demonstrating accelerated return of bowel funct

  • GlobeNewswire

    Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center

    $5.2M invested at $3.45 stock priceFunds to be used to advance clinical development of LB1148Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used as standard of care for the protection and healing of the GI tract in surgical patients if approved by the FDA CARLSBAD, Calif., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a late‐stage biopharma company advancing therapies for acute and chro